Fewer severe infections with tranexamic acid in patients with hematologic malignancies

CONCLUSION: Patients with hematologic malignancies who received TXA had less severe infections than those who received placebo with no difference in overall rate of infection or other inflammatory outcomes. Further investigation is needed on the impact of TXA on infections in this population.PMID:38666065 | PMC:PMC11043644 | DOI:10.1016/j.rpth.2024.102358

Source: Cell Research - April 26, 2024 Category: Cytology Authors: Jacqueline N Poston Siobhan P Brown Anton Ilich Amy Sarah Ginsburg Heather Herren Nahed El Kassar Christopher E Jensen Darrell J Triulzi Nigel S Key Susanne May Terry B Gernsheimer Source Type: research